We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for nivolumab (Bristol-Myers Squibb Australia Pty Ltd)
Active ingredients
nivolumab
Date of review outcome
Lapse date
Type
Priority review
Indication
Nivolumab in combination with ipilimumab, is indicated for the treatment of patients with intermediate/poor risk advanced renal cell carcinoma (RCC)
Registration date